Q3 revenues were up +9% (+9% at cc) to USD4,598m but gross profit margin weakened 70bp to 32.0%. EBITDA increased +9% to USD867m and net income attributable to shareholders strongly increased +27% to €333m. Operating CF clearly dropped 24% to USD439m, primarily driven by a swing in NWC (USD-164m after USD54m). Investing CF remained in the same territory (USD-273m after USD-281m), but FCF declined from US$298m to US$166m. Management confirmed FX guidance, expecting sales to grow +7-10% at
27 Oct 2016
Costs move ahead of revenues
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Costs move ahead of revenues
Fresenius Medical Care AG (FME:WBO) | 0 0 0.7% | Mkt Cap: 26,769m
- Published:
27 Oct 2016 -
Author:
Martin Schnee -
Pages:
3
Q3 revenues were up +9% (+9% at cc) to USD4,598m but gross profit margin weakened 70bp to 32.0%. EBITDA increased +9% to USD867m and net income attributable to shareholders strongly increased +27% to €333m. Operating CF clearly dropped 24% to USD439m, primarily driven by a swing in NWC (USD-164m after USD54m). Investing CF remained in the same territory (USD-273m after USD-281m), but FCF declined from US$298m to US$166m. Management confirmed FX guidance, expecting sales to grow +7-10% at